IDEA #2A4ETU Synthetic Carbohydrate Receptor Based Broad Spectrum Antivirals. 23A0030

We invented a new class of glycan-binding small molecules called synthetic carbohydrate receptors (SCRs). These molecules are easily synthesized with high yields and can be easily scaled up. We have successfully studied these SCRs for their anti SARS-CoV-2 and anti- MERS-CoV activities, as well as for their cytotoxicity levels. We observed the highest levels of antiviral activity against SARS-CoV-2/VSV and MERS-CoV-2/VSV pseudotyped virions, and these compounds also exhibited low to null levels of cytotoxicity. Interesting, besides having high antiviral activities against both coronaviral pseudotyped virions, some SCRs were also among the most potent against the flaviviruses, thereby demonstrating the BSA potential of these compounds